Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Departure Of Cfo (new) — Chief Financial Officer resigned effective June 5, 2026, with no external replacement announced.
  • Nasdaq Compliance Deficiency (new) — Company violated Nasdaq listing rules due to board vacancies and is not eligible for standard cure periods.
NASDAQ: TPST Tempest Therapeutics, Inc. 8-K

Tempest CFO resigns; company scrambles to fix Nasdaq board compliance after vacancies

Filed June 4, 2026 · Period ending May 29, 2026 · ~1 min read

Key Changes

  • high

    CFO Nicholas Maestas resigned effective June 5, 2026. Internal controller Justin Trojanowski promoted to Principal Financial Officer while keeping his existing roles—no external CFO search announced.

  • high

    Nasdaq notified Tempest on May 22 of listing rule violations due to multiple board vacancies. Company not eligible for standard cure periods and must submit compliance plan to exchange.

  • medium

    Two new directors appointed June 4: Dr. John Yee (Apnimed exec) and Drake Richey (financial advisor). Both join Audit, Compensation, and Governance committees. Company says one more independent director needed for full compliance.

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.

Partner

Trade TPST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify